Showing 3401-3410 of 9146 results for "".
- South Beach Symposium: Dr. Neal Neal Bhatia Maps a Fragmented but Promising Pipelinehttps://practicaldermatology.com/news/south-beach-symposium-dr-neal-neal-bhatia-maps-a-fragmented-but-promising-pipeline/2485624/At the 2026 South Beach Symposium, Neal Bhatia, MD, FAAD, delivered a wide-ranging and opinionated overview of the current dermatology therapeutic landscape, arguing that Innovation is uneven across disease states and increasi
- Nutrafol Launches Men 50+ Formula Targeting Age-Related Hair Thinninghttps://practicaldermatology.com/news/nutrafol-launches-men-50-formula-targeting-age-related-hair-thinning/2485568/Nutrafol announced an expansion of its men’s portfolio with the launch of Nutrafol Men 50+, a product designed specifically for men aged 50 years and older with thinning hair. According to the company, men entering their 50s ex
- AbbVie Files FDA, EMA Applications for Upadacitinib in Non-Segmental Vitiligohttps://practicaldermatology.com/news/abbvie-files-fda-ema-applications-for-upadacitinib-in-non-segmental-vitiligo/2485564/AbbVie has submitted regulatory applications to the US Food and Drug Administration and European Medicines Agency seeking approval of upadacitinib (RINVOQ) for the treatment of adults and adolescents with non-segmental vitiligo (NSV), according to a
- Drs. Neal Bhatia and Ted Rosen Present New Therapeutics ‘Popping’ in 2026https://practicaldermatology.com/news/drs-neal-bhatia-and-ted-rosen-present-new-therapeutics-popping-in-2026/2485511/In their annual overview of therapeutics at Maui Derm Hawaii 2026, Ted Rosen, MD, and Neal Bhatia, MD, used a K-Pop Demon Hunters theme to walk through emerging strategies across inflammatory skin diseases. Drs. Rosen and Bhatia emphasized a shift toward non‑steroidal topicals that can be
- RE-UNITE-PN Launched to Evaluate Nemolizumab in Prurigo Nodularishttps://practicaldermatology.com/news/re-unite-pn-launched-to-evaluate-nemolizumab-in-prurigo-nodularis/2485449/A new international, non-interventional study aims to provide critical real-world data on nemolizumab’s performance in patients with moderate-to-severe prurigo nodularis (PN). The RE-UNITE-PN study (NCT06988618), sponsored by Galderma, is designed to complement pivo
- New Data Show BMI Influences Psoriasis Severity and Systemic Inflammationhttps://practicaldermatology.com/news/new-data-show-bmi-influences-psoriasis-severity-and-systemic-inflammation/2485411/Obesity and overweight status were associated with higher baseline prevalence of cardiometabolic comorbidities, psoriatic arthritis (PsA), and systemic inflammation compared to individuals with normal BMI, according to new data from a poster at 2026 Winter Clinical
- No New Safety Signals in Broad Ruxolitinib Dataset, Including AD, Vitiligo, and AAhttps://practicaldermatology.com/news/no-new-safety-signals-in-broad-ruxolitinib-dataset-including-ad-vitiligo-and-aa/2485382/A new safety analysis presented at the 2026 Winter Clinical Dermatology Conference in Maui supporting the long-term tolerability of ruxolitinib cream (Opzelura®, Incyte) in a range of inflammatory skin conditions. The integrat
- Vixarelimab Shows Dose-Dependent Efficacy in Prurigo Nodularis Phase 2b Trialhttps://practicaldermatology.com/news/vixarelimab-shows-dose-dependent-efficacy-in-prurigo-nodularis-phase-2b-trial/2484982/Vixarelimab demonstrated dose-dependent improvements in itch severity and skin lesion clearance in patients with moderate to severe prurigo nodularis (PN), according to new results from a phase 2b randomized clinical trial. Res
- First Patient Enrolled in Nemolizumab Study for Chronic Itch Without Causehttps://practicaldermatology.com/news/first-patient-enrolled-in-nemolizumab-study-for-chronic-itch-without-cause/2484883/Galderma announced the enrollment first patient in a phase II clinical trial investigating nemolizumab for the treatment of Chronic Pruritus of Unknown Origin (CPUO), according to a press release from the manufacturer. The tr
- NIH Grants for Vitiligo Research Rise Over Time, Driven by Medical Schools and NIAMShttps://practicaldermatology.com/news/nih-grants-for-vitiligo-research-rise-over-time-driven-by-medical-schools-and-niams/2484513/Funding trends National Institutes of Health (NIH) funding trends shows steady, long-term support for vitiligo research from 1985 through 2024, according to a new analysis. Using the NIH Research Portfolio Online Reporting To